Science Will Win

Cancer research is moving faster than ever—but too many patients never feel the impact of that progress. Artificial Intelligence (AI) is emerging as one tool that could help change that.  In the Season 6 finale of Science Will Win, Dr. Raven Baxter follows the human journey behind AI in oncology—from the moment of diagnosis to the real‑world barriers that determine access to care.  Along the way, we explore how thoughtfully designed artificial intelligence is reshaping trial design, enrollment, eligibility, and access—helping patients regain agency and bridging the gap between scientific breakthroughs and real‑world cancer care. As the season concludes, one thing is clear: progress matters most when it reaches the people who need it. Featured guests: – Dr. Lionel Kankeu Fonkoua, Medical Oncologist and Translational Researcher, Mayo Clinic – Jeff Legos, Chief Oncology Officer, Pfizer – Dr. Ravi Parikh, Medical Oncologist; Director, Human‑Algorithm Collaboration Lab – Maya R. Said, Founder and CEO, Outcomes4Me Dive into the episode here: 00:00 – Past episodes introduce us to an emerging tech advancement 04:16 – What is a clinical trial? 07:35 – AI accelerating the pace of oncology 12:42 – Clinical trials and AI: How can it help? 16:17 – A gap between innovation and patient access 19:16 – Maya's story 23:47 – Clinical trials for AI tools  27:54 – Conclusion: building pathways alongside scientific innovation Check out our YouTube channel (@Pfizer) to watch full interviews between Raven & some of the patients featured. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. *The content in this episode is for informational purposes only and does not provide medical advice. Pfizer does not endorse or sponsor third‑party tools referenced. Patients should not use the tools described as a replacement for discussions with a healthcare provider. Patients should consult their healthcare provider regarding medical decisions. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What comes after a cancer diagnosis and treatment? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most important, and often overlooked, chapters for cancer patients: survivorship. As five-year survival rates climb to 70%, more people than ever are living with and beyond cancer. But longer survival brings its own complex challenges, and our care systems are still catching up. You'll hear from experts and advocates working at the intersection of medicine, policy, and community. We’ll discuss what it really takes to support people through this transition — when the clinical benchmarks have passed and it’s time to go back to “normal life”. From patient care plans and workplace disclosure to mental health, this episode makes one thing clear: survivorship demands dignity, support, and a whole new kind of care. Featured guests: – Tina Deignan, Commercial President, Pfizer Oncology – Shelley Fuld Nasso, CEO, Cancer Nation – Rebecca Nellis, Executive Director, Cancer and Careers – Bob Riter, Breast Cancer Patient & Advocate Dive into the episode here: 00:00 – The ongoing battle with cancer 03:43 – Rethinking survivorship 05:32 – The five-year survival myth 07:00 – The history of the term "survivor" 09:36 – Bob’s journey with breast cancer 11:38 – Lost in transition and survivorship care plans 14:25 – The intersection of cancer and work 18:49 – Rethinking how work gets done 20:00 – Disclosure and improving company culture 20:59 – The swivel technique 23:19 – Controlling your narrative 25:11 – Standardizing long-term survivorship care through policy 27:08 – Lack of access to care leads to disparities in survival rates 29:48 – Bob's second journey with cancer  32:21 – Takeaways and peek into our final episode Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Bob Riter on his cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What women carry through cancer is more than a diagnosis.  In our third episode of this miniseries, Dr. Raven Baxter explores how generations of women turned silence into advocacy and fear into progress, reshaping the perceptions and discussions around cancer over time. Through history, science, and a powerful story from Katrina M. Johnson — a woman who has lived through multiple breast cancer diagnoses and now advocates for others — the episode highlights how women continue to drive change in how cancer is understood, treated, and lived with. Featured guests: – Dr. Isaac Chan, Physician‑scientist and Assistant Professor, Department of Internal Medicine, University of Texas Southwestern – Kirsten Gardner, Director of Medical Humanities, University of Texas at San Antonio; Author – Katrina M. Johnson, Breast Cancer Patient; Director of Advocacy and Professional Relations, Pfizer Oncology Dive into the episode here: 00:00 – The start of three cancer diagnoses 02:06 – The history of breast cancer awareness campaigns 09:27 – How the mastectomy has changed 12:59 – Evolving research in breast cancer 15:10 – Breast cancer impacting body image and sexuality 19:29 – Emerging therapies to address breast cancer 21:18 – Addressing the BRCA gene today 23:30 – Breast cancer advocacy then and now 26:08 – Katrina's takeaways about her breast cancer story Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Katrina M. Johnson on her breast cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if the key to treating cancer was hiding in plain sight – written into its DNA? In this episode of Science Will Win, host Dr. Raven Baxter explores one of the most exciting breakthroughs in cancer care today: the discovery of biomarkers. These tiny molecular signals are helping doctors understand what’s really driving an individual person’s cancer – and opening the door to treatments that can dramatically change patient outcomes. You’ll hear powerful stories from people whose cancers were traced back to a specific biomarker, alongside experts who break down what biomarker testing is, how it works, and why it’s transforming the way we think about cancer treatment.    Biomarkers are showing us that when we understand cancer at its molecular level, a disease that once felt like an unsolvable mystery starts to come into focus. Featured guests: – Dr. Ross Camidge, Director of Thoracic Oncology, University of Colorado – Kelly Huffman, Lung Cancer Patient and Retail Account Manager, Pfizer – Karin Tollefson, Chief Oncology Medical Officer, Pfizer Dive into the episode here: 00:00 – An oncologist’s diagnosis introduces the world of biomarker 03:10 – Defining biomarkers and its history 06:24 – Discovery of the first lung cancer biomarker 08:39 – The start Kelly’s lung cancer journey 16:00 – Biomarkers: how do you test for them? 19:11– Discovery of ALK biomarker shift’s Kelly’s story 22:34 – Landscape of targeted therapy and lung cancer today 25:24 – Moving forward with targeted treatments and conclusion Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Kelly Huffman on her lung cancer journey. Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why are more young adults getting cancer? That's one of the most pressing questions facing the scientific community today. Traditionally thought of as a disease that affects aging populations, recent data shows that cancer diagnoses for people under the age of 50 are increasing. To tackle this problem, it’ll take a global effort. In this episode you’ll hear from patients, oncologists, researchers and health care providers who are coming together to address this issue head on. Featured guests:– Dr. Marshall Anthony Jr., social scientist and colorectal cancer patient– Dr. Johanna Bendell, Chief Development Officer of Oncology, Pfizer– Dr. Yin Cao, molecular cancer epidemiologist; Cao Lab leader, Washington University– Dr. Beatrice Dionigi, colorectal cancer surgeon; founder & co‑director, Early Onset Colon and Rectal Cancer Project, Columbia Research Cancer Center– Dr. Susan Zhang, Global Development Lead, Pfizer OncologyDive into the episode here:00:00 – A patient story reveals an alarming new trend6:30 – The data behind the rise of early-onset cancer 10:39 – The global search for a cause  14:13 – The unique challenges facing young people with cancer 20:28 – Screening guidelines and what to expect from a colonoscopy  25:17 – The importance of early detection  27:59 – The conclusion of Marshall's cancer journey 30:23 – What's next, and closing thoughts Check out our YouTube channel (@Pfizer) to watch the full interview with Raven & Dr. Marshall Anthony Jr. on his colorectal cancer journey.Season 6 of Science Will Win is created by Pfizer and hosted by Dr. Raven Baxter. It’s produced by Acast Creative Studios. Hosts in this podcast series were compensated for their time. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.